Page 30 - Pharma

Gates Foundation invests $ 5 mn in Amyris to reduce cost of malaria treatment

The program will focus on the continued production and secure supplies of artemisinic acid and amorphadiene to be converted to artemisinin for use in artemisinin combination therapies (ACTs)

US FDA grants approval to Sun Pharma's ophthalmic drug bromfenac

Developed by InSite Vision, which was acquired by Sun Pharma in November 2015, BromSite is likely to be commercialised in the second half of 2016

Biosimilars to help health systems in US and Europe save $ 110 bn by 2020

Surge in biosimilars to drive significant change in health system costs, patient access and competition by 2020, says an IMS Health study

Pfizer and Allergan calls of their $160 bn merger deal

In connection with the termination of the merger agreement, Pfizer has agreed to pay Allergan $150 million for reimbursement of expenses associated with the transaction

Dr Reddy's Labs ties up with US-based Cutis Pharma for API & drug research

Joint development agreement will accelerate NDA (new drug application) filing and worldwide commercialisation of select products in Cutis Pharma's R&D portfolio

Fragrance & flavour maker S H Kelkar buys Rasiklal Hemani Agencies for Rs 28 cr

Meanwhile, Keva Flavours, a subsidiary of S H Kelkar, has acquired Hi-Tech Technologies (HTT) for total consideration of Rs 25.11 crore

Prosthetic & therapeutic robotics market to reach $ 3.6 bn in 2025

While the large markets for the prosthetic robotics will reside in developed countries in Europe and the US, China will comprise nearly one-third of the total 2025 market, says Lux Research

Doctors advocate better diagnostic algorithms to fight multi drug resistant TB

Over one third of TB cases in India are not accurately diagnosed, leading to rise in MDR/XDR cases of TB

Roche to initiate testing for Zika virus in US

The new cobas Zika test will screen blood samples on the cobas 6800/8800 systems

How to be a successful medical entrepreneur: Dr Dharminder Nagar

The article offers useful tips to maintain a successful foothold in medical entrepreneurship

Rusan Pharma aims to double turnover to Rs 600 cr by 2018

The company will invest Rs 100 crores in R&D and manufacturing unit at Kandla and plans to expand its exports business

Dishman buys partner's 50% stake in JV Schutz Dishman

The acquisition will help Dishman in backward integration for some of its existing products and for manufacturing other APIs

Dr Reddy's inks licensing pact for Eisai's investigational anticancer agent E7777

While Dr Reddy's will be granted exclusive rights for US, Europe and certain emerging markets, the Japanese firm will be responsible for development and marketing of E7777 in Japan and Asia

Aurobindo Pharma receives US FDA nod for antibiotic drug polymyxin B

The approved product, polymyxin B injection, has an estimated market size of $ 7.6 million for the twelve months ending February 2016, according to IMS

Lupin launches insomnia drug zolpidem in US

The generic version of Intermezzo tablet, the drug is the first product launch from Lupin's GAVIS pipeline with 180 days exclusivity

Transilwrap acquires Dow's global specialty films business

Dow's film technologies, market focus and geographic presence support Transilwrap's accelerated growth in strategic market segments such as healthcare and packaging

Zydus acquires Actibile brand from Albert David

The acquisition is expected to strengthen Zydus Group's presence in gastroenterology segment

Panacea Biotec launches prostate cancer drug Cabapan

Cabapan has been developed by Panacea Biotec's global research and development center located at Mumbai

Jubilant Innovation to receive upfront payment $4.6 mn from venture funding

It will also receive contingent payments up to $ 18 million from its 10% interest as a limited partner in one of the venture funds specialised in investing in early stage drug discovery firms

Dr Reddy's enters into licensing pact for XenoPort's under-trial psoriasis drug in US

As per the agreement, XenoPort will receive a $47.5 million up-front payment and an additional $2.5 million for transfer of certain clinical trial materials to Dr Reddy's Laboratories